Geron Corporation announced that its management team will present at the Bank of America Securities 2026 Healthcare Conference on May 12 and the Stifel Virtual Targeted Oncology Forum on May 20. These presentations will provide updates on Geron's commercial-stage biopharmaceutical developments, including its approved telomerase inhibitor RYTELO® for certain blood cancers and ongoing Phase 3 trials. Investors can access live and archived webcasts on Geron's website. This engagement highlights Geron's efforts to advance treatments for blood cancer and keep investors informed on progress and clinical developments.
Toescoin, a memecoin on the Solana blockchain, announced talks with a major Japanese venture capital firm interested in investing up to $250,000 over time. This engagement aims to provide both funding and strategic support as Toescoin expands its pre...
A new patent application reveals a quantum AI project creating humanoid robots that can carry a person's 'digital DNA' to live alongside humans for centuries. This technology, part of a federally registered clinical trial, allows families to preserve...
TRX price remains stable near $0.33, supported by Tron Inc.'s ongoing treasury purchases and robust USDT transaction volume on the TRON network. Despite some weakening momentum indicators, buyers defend key support levels within an ascending channel....
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging the company may have provided misleading business information to investors in its stock-based mutual funds. Investors who purchased Pu...
Storj Labs filed for Chapter 11 bankruptcy to address old debts that it cannot resolve through growth. Despite the filing, the Storj network and STORJ tokens continue to operate normally. The company plans to offer token holders equity in the reorgan...
